Freedom Meditech Appoints Daniel M. Bradbury as Chairman of the Board of Directors
SAN DIEGO, Sept. 24, 2014 /PRNewswire/ -- Freedom Meditech, Inc. today announced the appointment of Daniel M. Bradbury as chairman of the board of directors. Mr. Bradbury is the managing member of BioBrit, LLC, and former CEO of Amylin Pharmaceuticals, Inc.
"Mr. Bradbury comes to us with extensive leadership experience in the diabetes space," said Keith Ignotz, CEO of Freedom Meditech. "Mr. Bradbury's insight brings tremendous value in the early stages of market adoption for the ClearPath DS-120™."
"Early detection of diabetes is among the most important global health issues. Freedom Meditech has developed and commercialized a unique technology to do this non-invasively, giving the company a significant opportunity to successfully address this unmet need," said Mr. Bradbury. "I am excited to join this dynamic organization that continues to provide better options for patients.
About Daniel Bradbury
Mr. Bradbury is a life sciences executive with more than 30 years of experience creating and implementing strategies that transform businesses and bring novel medicines to market. He is currently managing member of BioBrit, LLC, a life sciences consulting and investment firm. Prior to that, Mr. Bradbury served as Amylin Pharmaceuticals' president, chief executive officer and director from 2007 until its acquisition by Bristol-Myers Squibb Company in 2012. During Mr. Bradbury's 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. Prior to joining Amylin, Mr. Bradbury worked in marketing and sales roles for 10 years at SmithKline Beecham Pharmaceuticals.
Mr. Bradbury serves on the board of directors of Corcept Therapeutics, Geron Corporation, Illumina, Inc., BioMed Realty, Biocon Limited, Castle Biosciences, Inc., DiaVacs, Inc., Liquid Grids, Inc., Microdermis, Inc., and Sensulin, Inc. He also serves on the board of trustees of the Keck Graduate Institute, the Investor Growth Capital advisory board, and the BioMed Ventures advisory committee. In addition to his board positions, Mr. Bradbury serves on the University of California, San Diego's Rady School of Management's advisory council and the University of Miami's Innovation Corporate advisory council. He received a bachelor's in pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
About Freedom Meditech
Freedom Meditech, Inc. is a medical device company focused on the commercialization of novel ophthalmic technologies for the detection of disease and management of patient health. The company's first product, the ClearPath DS-120™, a non-invasive tool for the measurement of autofluorescence in the eye has been cleared by the FDA, and has obtained the CE mark and a Canadian Establishment license. I-SugarX is the company's second product currently in development as a non-invasive ophthalmic glucose monitor that measures glucose levels in the eye for people with diabetes. The company maintains corporate and engineering operations in San Diego, CA with supporting research and development activities throughout the state of Ohio. For more information, visit www.freedom-meditech.com or find us on Twitter, Facebook and LinkedIn.
SOURCE Freedom Meditech, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article